CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
John Hanna, chief executive officer of CareDx, said the company is focused on markets where it believes it can hold leading positions, particularly areas involving high-cost diseases, concentrated specialist providers and repeat testing. He said CareDx has about 750 employees, including roughly 200 focused on customers and patients, 110 scientists and researchers and about 80 software programmers.
